09/01/2010

"Deciphering The Regulations For Facility Design and Environmental Control"

Wai Wong, General Manager & VP Worldwide Operations

With the FDA under fire in recent years regarding the quality of inspections, the effect on biotech, pharmaceutical, and medical device companies has been to err on the safe side of regulatory requirements by proving more evidence wherever they can.

DOWNLOAD ARTICLE
09/01/2010

"Point of View: Gauging Regulatory Effectiveness"

Bikash Chatterjee, President & CTO

That the pharmaceutical and biotech industry is in a state of flux is undeniable. Shifts within the U.S. marketplace have intensified the pressures on industry to perform, while the FDA has been struggling with its own charter.

DOWNLOAD ARTICLE
09/01/2010

"A QbD Implementation Roadmap for the Generics Industry"

Bikash Chatterjee, President & CTO

The passage of H.R. 3962, the Affordable Health Care for America Act of 2009, has changed the healthcare landscape forever, kicking up dust in the U.S. pharmaceutical marketplace.

DOWNLOAD ARTICLE
08/01/2010

"The Devil Is In The Details"

Bikash Chatterjee, President & CTO

Consolidation on a massive scale amongst the elite of the U.S. pharmaceutical industry raises questions about how to remain competitive, and profound changes to the marketplace can be seen on all fronts.

DOWNLOAD ARTICLE
06/01/2010

"Special Report: RFID in Pharma Today"

Bikash Chatterjee, President & CTO

A year ago, at INTERPHEX, the RFID Security Alliance described the considerations in implementing RFID as a security solution within the global supply chain (GSC), with regard to asset tracking.

DOWNLOAD ARTICLE
06/01/2010

"Pharma’s Changing Strategic Planning Landscape"

Bikash Chatterjee, President & CTO

The last few years in the pharmaceutical industry have seen unprecedented upheaval, with changes to the marketplace on all fronts. In the U.S., consolidation on a massive scale amongst the elite of the industry raises new questions about competitiveness and
what it takes to keep it.

DOWNLOAD ARTICLE
04/01/2010

"Meeting The Global Compliance Challenge"

Bikash Chatterjee, President & CTO

There can be no doubt that the last decade for the pharmaceutical and biotech industry has been full of extraordinary change. Regulatory changes culminating in the FDA’s 2004 guidance A Risk-based Approach to CGMPs underscored the reality that as an industry we needed to evolve.

DOWNLOAD ARTICLE
03/01/2010

"Chinas Bold Step Toward Parity"

Bikash Chatterjee, President & CTO

Chatterjee discusses the factors driving China’s transformation from low-cost manufacturing to more sophisticated quality matters.

DOWNLOAD ARTICLE
03/01/2010

"Achieving Bottom Line Continuous Improvement Value"

Bikash Chatterjee, President & CTO

As the U.S. pharmaceutical and biotechnology markets ebb and flow, one truth cannot be argued: sustainability is the provenance of companies that can adapt to the new marketplace and deliver on business performance.

DOWNLOAD ARTICLE
01/01/2010

"Pharma’s Tenuous Commitment to Lean"

Bikash Chatterjee, President & CTO

There is an old saying that “change is inevitable… adapting to change is unavoidable; it’show you do it that sets you together or apart.”1 Looking closely at how we have developed products, defined quality assurance and demonstrated regulatory compliance, the last five
years have been remarkable in terms of coping with change.

DOWNLOAD ARTICLE